Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea
NCT05616923
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
12
Enrollment
OTHER
Sponsor class
Conditions
Rosacea, Erythematotelangiectatic
Interventions
DRUG:
Trametinib
Sponsor
Albany Research Institute, Inc.